Stay updated on Copanlisib and Nivolumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.

Latest updates to the Copanlisib and Nivolumab in Lymphoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded a Locations section listing trial sites in Alabama, Iowa, Kansas, Kentucky, Minnesota, Missouri, New Hampshire, North Carolina, and Utah. Removed the HHS Vulnerability Disclosure link and updated the page revision to v3.3.3.SummaryDifference0.9%

- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2 on the page, with no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page no longer displays a general funding/status notice; this is a site-wide message removal and does not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check67 days agoChange DetectedThe two screenshots show no changes to core study information (title, NCT03484819, sponsor, eligibility criteria, interventions, and locations) and no new sections or data appear. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check95 days agoChange Detected- Added a government funding notice and operating status guidance, and updated the version to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference2%

- Check102 days agoChange DetectedUpdated page to version v3.1.0 and removed the topic 'Diffuse large B-cell lymphoma' from resources; this reduces a core topic from the content.SummaryDifference0.3%

Stay in the know with updates to Copanlisib and Nivolumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.